Form SC 13D Sarepta Therapeutics, Filed by: Barry Richard
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Baird Upgrades Sarepta Therapeutic (SRPT) to Outperform; Favorable Risk/Reward
May 6, 2015 6:10 AM EDTBaird upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Neutral to Outperform with a price target of $20.00 (from $16.00), citing favorable risk/reward into FDA guidance.
Analyst Brian Skorney commented, "We're jumping back into the stock after last week's NDA submission by potential competitor... More
Sarepta Therapeutics (SRPT) New Board Member Rick Barry Files 13D
May 5, 2015 3:50 PM EDTSarepta Therapeutics (NASDAQ: SRPT) is active after Rick Barry filed a 13D showing a 7.66% stake, or 3,165,014. Rick Barry has been nominated to join the Board of Directors of the Issuer, Sarepta Therapeutics, and has accepted the nomination.
SI NOTE: Barry has been a... More
